This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nuwellis, Inc. Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health CI
Nuwellis, Inc. Announces Results from Two New Clinical Data Analyses from the AVOID-HF Trial, Which Demonstrate the Benefits of its Aquadex System in Reducing Heart Failure Readmissions at 30 Days CI
Nuwellis, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Transcript : Nuwellis, Inc., Q4 2023 Earnings Call, Mar 05, 2024
Earnings Flash (NUWE) NUWELLIS Reports Q4 Revenue $2.6M MT
Certain Warrants of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024. CI
Certain Stock Options of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024. CI
Certain Common Stock of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024. CI
Nuwellis Receives FDA Approval for Specialized Catheter MT
Nuwellis, Inc. Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter CI
Nuwellis, Inc. Announces New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring Foriatric Patients CI
Ladenburg Thalmann Downgrades Nuwellis to Neutral From Buy MT
Nuwellis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Nuwellis, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Earnings Flash (NUWE) NUWELLIS Reports Q3 Revenue $2.4M MT
Nuwellis, Inc. Announces Board of Directors Transition CI
Nuwellis Provides Regulatory Update on Seastar Medical's Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under A Humanitarian Device Exemption CI
Top Premarket Decliners MT
Nuwellis, Inc. Appoints Robert B. Scott as Chief Financial Officer, Effective September 2, 2023 CI
Nuwellis Unveils CFO Transition Plan MT
Transcript : Nuwellis, Inc., Q2 2023 Earnings Call, Aug 08, 2023
Earnings Flash (NUWE) NUWELLIS Reports Q2 Revenue $2.1M, vs. Street Est of $2.19M MT
Nuwellis, Inc. Announces Resignation of Lynn Blake as Chief Financial Officer, Effective September 1, 2023 CI
Nuwellis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Nuwellis Signs Supply, Collaboration Agreement With DaVita for Aquadex Ultrafiltration Therapy Pilot Program MT
Chart Nuwellis, Inc.
More charts
Nuwellis, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
0.1678 USD
Average target price
5.25 USD
Spread / Average Target
+3,028.72%
Consensus
  1. Stock Market
  2. Equities
  3. NUWE Stock
  4. News Nuwellis, Inc.
  5. Earnings Flash (NUWE) NUWELLIS Reports Q2 Revenue $2.1M, vs. Street Est of $2.19M